{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T07:26:21Z","timestamp":1774509981796,"version":"3.50.1"},"reference-count":136,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2016,5,27]],"date-time":"2016-05-27T00:00:00Z","timestamp":1464307200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Tumor Biol."],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s13277-016-5083-1","type":"journal-article","created":{"date-parts":[[2016,5,27]],"date-time":"2016-05-27T06:43:36Z","timestamp":1464331416000},"page":"11541-11551","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["mTOR inhibitors in urinary bladder cancer"],"prefix":"10.1007","volume":"37","author":[{"given":"R.","family":"Pinto-Leite","sequence":"first","affiliation":[]},{"given":"R.","family":"Arantes-Rodrigues","sequence":"additional","affiliation":[]},{"given":"Nuno","family":"Sousa","sequence":"additional","affiliation":[]},{"given":"P. A.","family":"Oliveira","sequence":"additional","affiliation":[]},{"given":"L.","family":"Santos","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2016,5,27]]},"reference":[{"issue":"4","key":"5083_CR1","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","volume":"64","author":"M Babjuk","year":"2013","unstructured":"Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Comp\u00e9rat E, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013;64(4):639\u201353.","journal-title":"Eur Urol"},{"issue":"4","key":"5083_CR2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","volume":"59","author":"A Jemal","year":"2009","unstructured":"Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"5083_CR3","first-page":"47","volume":"84","author":"M Racioppi","year":"2012","unstructured":"Racioppi M, Palermo G, D\u2019Addessi A, Pinto F, Sacco E, D\u2019Agostino D, et al. Hot topics in urological health economics. A mini review. Arch Ital Urol Androl. 2012;84(2):47\u201352.","journal-title":"Arch Ital Urol Androl"},{"key":"5083_CR4","unstructured":"Cancer Research UK. Bladder cancer statistics\u2014key facts. http:\/\/info.cancerresearchuk.org\/cancerstats\/keyfacts\/bladder-cancer\/ . Accessed June 2012."},{"issue":"3","key":"5083_CR5","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00345-009-0383-3","volume":"27","author":"M Ploeg","year":"2009","unstructured":"Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009;27(3):289\u201393.","journal-title":"World J Urol"},{"key":"5083_CR6","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ucl.2015.01.005","volume":"42","author":"DC Johnson","year":"2015","unstructured":"Johnson DC, Greene PS, Nielsen ME. Surgical advances in bladder cancer: at what cost? Urol Clin North Am. 2015;42:235\u201352.","journal-title":"Urol Clin North Am"},{"issue":"12","key":"5083_CR7","doi-asserted-by":"crossref","first-page":"e115870","DOI":"10.1371\/journal.pone.0115870","volume":"9","author":"BM Wittmann","year":"2014","unstructured":"Wittmann BM, Stirdivant SM, Mitchell MW, Wulff JE, McDunn JE, Li Z, et al. Bladder cancer biomarker discovery using global metabolomic profiling of urine. PLoS One. 2014;9(12):e115870.","journal-title":"PLoS One"},{"key":"5083_CR8","unstructured":"American Cancer Society. Bladder cancer; survival rates for bladder cancer by stage. http:\/\/www.cancer.org\/cancer\/bladdercancer\/detailedguide\/bladder-cancer-survival-rates . Accessed October 2014."},{"issue":"9685","key":"5083_CR9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(09)60491-8","volume":"374","author":"DS Kaufman","year":"2009","unstructured":"Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009;374(9685):239\u201349.","journal-title":"Lancet"},{"key":"5083_CR10","unstructured":"Chou R, Buckley D, Fu R, Gore JL, Gustafson K, Griffin J, Grusing S, Selph S. Emerging approaches to diagnosis and treatment of non\u2013muscle-invasive bladder cancer. Rockville (MD): Agency for Healthcare Research and Quality (US). 2015;15(16):EHC017\u2013EF"},{"issue":"3","key":"5083_CR11","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.eururo.2009.06.028","volume":"56","author":"BW Rhijn van","year":"2009","unstructured":"van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, et al. Recurrence and progression of disease in non-muscle invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009;56(3):430\u201342.","journal-title":"Eur Urol"},{"issue":"10","key":"5083_CR12","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1038\/bjc.2015.109","volume":"112","author":"S Hafeez","year":"2015","unstructured":"Hafeez S, Horwich A, Omar O, Mohammed K, Thompson A, Kumar P, et al. Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder. Br J Cancer. 2015;112(10):1626\u201335.","journal-title":"Br J Cancer"},{"issue":"6","key":"5083_CR13","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.eururo.2011.03.023","volume":"59","author":"A Stenzl","year":"2011","unstructured":"Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU Guidelines. Eur Urol. 2011;59(6):1009\u201318.","journal-title":"Eur Urol"},{"issue":"5","key":"5083_CR14","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3109\/10408363.2015.1033610","volume":"52","author":"F Sanguedolce","year":"2015","unstructured":"Sanguedolce F, Cormio A, Bufo P, Carrieri G, Cormio L. Molecular markers in bladder cancer: novel research frontiers. Crit Rev Clin Lab Sci. 2015;52(5):242\u201355.","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"2","key":"5083_CR15","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ucl.2015.01.006","volume":"42","author":"EJ Jordan","year":"2015","unstructured":"Jordan EJ, Iyer G. Targeted therapy in advanced bladder cancer: what have we learned? Urol Clin North Am. 2015;42(2):253\u201362.","journal-title":"Urol Clin North Am"},{"key":"5083_CR16","first-page":"372","volume":"9","author":"FS Collins","year":"2015","unstructured":"Collins FS, Varmus H. A New Initiative on Precision Medicine. N Engl J Med. 2015;9:372.","journal-title":"N Engl J Med"},{"issue":"6","key":"5083_CR17","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.3390\/nu5062231","volume":"5","author":"GA Soliman","year":"2013","unstructured":"Soliman GA. The role of mechanistic target of rapamycin (mTOR) complexes signaling in the immune responses. Nutrients. 2013;5(6):2231\u201357.","journal-title":"Nutrients"},{"issue":"11","key":"5083_CR18","doi-asserted-by":"crossref","first-page":"20753","DOI":"10.3390\/ijms151120753","volume":"15","author":"X Zheng","year":"2014","unstructured":"Zheng X, Liang Y, He Q, Yao R, Bao W, Bao L, et al. Current models of mammalian target of rapamycin complex 1 (mTORC1) activation by growth factors and amino acids. Int J Mol Sci. 2014;15(11):20753\u201369.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"5083_CR19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11523-011-0167-8","volume":"6","author":"JS Carew","year":"2011","unstructured":"Carew JS, Kelly KR, Nawrocki ST. Mechanisms of mTOR inhibitor resistance in cancer therapy. Target Oncol. 2011;6(1):17\u201327.","journal-title":"Target Oncol"},{"issue":"11","key":"5083_CR20","doi-asserted-by":"crossref","first-page":"e81649","DOI":"10.1371\/journal.pone.0081649","volume":"8","author":"MJ Groenewoud","year":"2013","unstructured":"Groenewoud MJ, Goorden SM, Kassies J, Pellis-van Berkel W, Lamb RF, Elgersma Y, et al. Mammalian target of rapamycin complex I (mTORC1) activity in ras homologue enriched in brain (Rheb)-deficient mouse embryonic fibroblasts. PLoS One. 2013;8(11):e81649.","journal-title":"PLoS One"},{"key":"5083_CR21","doi-asserted-by":"crossref","first-page":"686984","DOI":"10.1155\/2014\/686984","volume":"2014","author":"M Showkat","year":"2014","unstructured":"Showkat M, Beigh MA, Andrabi KI. mTOR signaling in protein translation regulation: implications in cancer genesis and therapeutic interventions. Mol Biol Int. 2014;2014:686984.","journal-title":"Mol Biol Int"},{"issue":"46","key":"5083_CR22","doi-asserted-by":"crossref","first-page":"40386","DOI":"10.1074\/jbc.M111.282590","volume":"286","author":"CH Chen","year":"2011","unstructured":"Chen CH, dos Sarbassov D. The mTOR (mammalian target of rapamycin) kinase maintains integrity of mTOR complex 2. J Biol Chem. 2011;286(46):40386\u201394.","journal-title":"J Biol Chem"},{"issue":"6","key":"5083_CR23","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2174\/138920310791824093","volume":"11","author":"H Zhou","year":"2010","unstructured":"Zhou H, Huang S. The complexes of mammalian target of rapamycin. Curr Protein Pept Sci. 2010;11(6):409\u201324.","journal-title":"Curr Protein Pept Sci"},{"key":"5083_CR24","first-page":"a008771","volume":"4","author":"CM Huang","year":"2012","unstructured":"Huang CM, Garcia-Haro L, Sparks CA, Guertin DA. mTOR-dependent cell survival mechanisms. Cold Spring Harb Perspect Biol. 2012;4:a008771.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"5083_CR25","doi-asserted-by":"crossref","unstructured":"Hayat MA. Autophagy: cancer, other pathologies, inflammation, immunity, infection and aging. 1st ed. Academic Press; 2014.","DOI":"10.1016\/B978-0-12-405877-4.00001-9"},{"issue":"1","key":"5083_CR26","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2174\/138920311795659407","volume":"12","author":"H Zhou","year":"2011","unstructured":"Zhou H, Huang S. Role of mTOR signaling in tumor cell motility, invasion and metastasis. Curr Protein Pept Sci. 2011;12(1):30\u201342.","journal-title":"Curr Protein Pept Sci"},{"issue":"1","key":"5083_CR27","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1042\/BJ20102103","volume":"436","author":"LR Pearce","year":"2011","unstructured":"Pearce LR, Sommer EM, Sakamoto K, Wullschleger S, Alessi DR. Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney. Biochem J. 2011;436(1):169\u201379.","journal-title":"Biochem J"},{"issue":"19","key":"5083_CR28","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.1158\/1078-0432.CCR-09-0898","volume":"15","author":"FM Platt","year":"2009","unstructured":"Platt FM, Hurst CD, Taylor CF, Gregory WM, Harnden P, Knowles MA. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res. 2009;15(19):6008\u201317.","journal-title":"Clin Cancer Res"},{"issue":"3\u20134","key":"5083_CR29","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10555-009-9198-3","volume":"28","author":"MA Knowles","year":"2009","unstructured":"Knowles MA, Platt FM, Ross RL, Hurst CD. Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer Metastasis Rev. 2009;28(3\u20134):305\u201316.","journal-title":"Cancer Metastasis Rev"},{"key":"5083_CR30","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/ijc.28518","volume":"134","author":"J Calderaro","year":"2014","unstructured":"Calderaro J, Rebouissou S, Koning L, Masmoudi A, Herault A, Maille PD, et al. PI3K\/AKT pathway activation in bladder carcinogenesis. Int J Cancer. 2014;134:1776\u201384.","journal-title":"Int J Cancer"},{"issue":"12","key":"5083_CR31","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1093\/carcin\/bgp258","volume":"30","author":"M Chen","year":"2009","unstructured":"Chen M, Cassidy A, Gu J, Delclos GL, Zhen F, Yang H, et al. Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk. Carcinogenesis. 2009;30(12):2047\u201352.","journal-title":"Carcinogenesis"},{"issue":"12","key":"5083_CR32","doi-asserted-by":"crossref","first-page":"130185","DOI":"10.1098\/rsob.130185","volume":"3","author":"MJ Groenewoud","year":"2013","unstructured":"Groenewoud MJ, Zwartkruis FJ. Rheb and mammalian target of rapamycin in mitochondrial homoeostasis. Open Biol. 2013;3(12):130185.","journal-title":"Open Biol"},{"issue":"6","key":"5083_CR33","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.tibs.2011.03.006","volume":"36","author":"MC Mendoza","year":"2011","unstructured":"Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011;36(6):320\u20138.","journal-title":"Trends Biochem Sci"},{"issue":"4","key":"5083_CR34","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/jmcb\/mjq038","volume":"3","author":"X Wang","year":"2011","unstructured":"Wang X, Proud CG. mTORC1 signaling: what we still don\u2019t know. J Mol Cell Biol. 2011;3(4):206\u201320.","journal-title":"J Mol Cell Biol"},{"issue":"11","key":"5083_CR35","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1021\/bi902135e","volume":"49","author":"S Vega-Rubin-de-Celis","year":"2010","unstructured":"Vega-Rubin-de-Celis S, Abdallah Z, Kinch L, Grishin NV, Brugarolas J, Zhang X. Structural analysis and functional implications of the negative mTORC1 regulator REDD1. Biochemistry. 2010;49(11):2491\u2013501.","journal-title":"Biochemistry"},{"issue":"6","key":"5083_CR36","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/ncb2763","volume":"15","author":"CC Dibble","year":"2013","unstructured":"Dibble CC, Manning BD. Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat Cell Biol. 2013;15(6):555\u201364.","journal-title":"Nat Cell Biol"},{"issue":"9","key":"5083_CR37","doi-asserted-by":"crossref","first-page":"954","DOI":"10.18632\/oncotarget.652","volume":"3","author":"JA McCubrey","year":"2012","unstructured":"McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, et al. Mutations and deregulation of Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR cascades which alter therapy response. Oncotarget. 2012;3(9):954\u201387.","journal-title":"Oncotarget"},{"issue":"6","key":"5083_CR38","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1128\/MCB.01079-13","volume":"34","author":"Y Martineau","year":"2014","unstructured":"Martineau Y, Wang X, Alain T, Petroulakis E, Shahbazian D, Fabre B, et al. Control of Paip1-eukayrotic translation initiation factor 3 interaction by amino acids through S6 kinase. Mol Cell Biol. 2014;34(6):1046\u201353.","journal-title":"Mol Cell Biol"},{"issue":"18","key":"5083_CR39","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1101\/gad.17420111","volume":"25","author":"DG Hardie","year":"2011","unstructured":"Hardie DG. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev. 2011;25(18):1895\u2013908.","journal-title":"Genes Dev"},{"issue":"7","key":"5083_CR40","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.febslet.2011.03.010","volume":"585","author":"A Alexander","year":"2011","unstructured":"Alexander A, Walker CL. The role of LKB1 and AMPK in cellular responses to stress and damage. FEBS Lett. 2011;585(7):952\u20137.","journal-title":"FEBS Lett"},{"issue":"8","key":"5083_CR41","doi-asserted-by":"crossref","first-page":"6128","DOI":"10.1074\/jbc.M110.166991","volume":"286","author":"I Tato","year":"2011","unstructured":"Tato I, Bartrons R, Ventura F, Rosa JL. Amino acids activate mammalian target of rapamycin complex 2 (mTORC2) via PI3K\/Akt signaling. J Biol Chem. 2011;286(8):6128\u201342.","journal-title":"J Biol Chem"},{"issue":"12","key":"5083_CR42","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.tibs.2009.09.004","volume":"34","author":"N Cybulski","year":"2009","unstructured":"Cybulski N, Hall MN. TOR complex 2: a signaling pathway of its own. Trends Biochem Sci. 2009;34(12):620\u20137.","journal-title":"Trends Biochem Sci"},{"issue":"2","key":"5083_CR43","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11912-012-0227-y","volume":"14","author":"L Willems","year":"2012","unstructured":"Willems L, Tamburini J, Chapuis N, Lacombe C, Mayeux P, Bouscary D. PI3K and mTOR signaling pathways in cancer: new data on targeted therapies. Curr Oncol Rep. 2012;14(2):129\u201338.","journal-title":"Curr Oncol Rep"},{"key":"5083_CR44","doi-asserted-by":"crossref","unstructured":"Sekiyama N, Arthanari H, Papadopoulos E, Rodriguez-Mias RA, Wagner G, L\u00e9ger-Abraham M. Molecular mechanism of the dual activity of 4EGI-1: dissociating eIF4G from eIF4E but stabilizing the binding of unphosphorylated 4E-BP1. Proc Natl Acad Sci USA. 2015","DOI":"10.1073\/pnas.1512118112"},{"issue":"4","key":"5083_CR45","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/annonc\/mdi113","volume":"16","author":"S Vignot","year":"2005","unstructured":"Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol. 2005;16(4):525\u201337.","journal-title":"Ann Oncol"},{"issue":"4","key":"5083_CR46","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1128\/MCB.00601-09","volume":"30","author":"LA Julien","year":"2010","unstructured":"Julien LA, Carriere A, Moreau J, Roux PP. mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol Cell Biol. 2010;30(4):908\u201321.","journal-title":"Mol Cell Biol"},{"issue":"11","key":"5083_CR47","doi-asserted-by":"crossref","first-page":"e27509","DOI":"10.1371\/journal.pone.0027509","volume":"6","author":"R Nawroth","year":"2011","unstructured":"Nawroth R, Stellwagen F, Schulz WA, Stoehr R, Hartmann A, Krause BJ, et al. S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer. PLoS One. 2011;6(11):e27509.","journal-title":"PLoS One"},{"issue":"3","key":"5083_CR48","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/01.mol.0000169352.35642.06","volume":"16","author":"A Soliman","year":"2005","unstructured":"Soliman A. The mammalian target of rapamycin signalling network and gene regulation. Curr Opin Lipidol. 2005;16(3):317\u201323.","journal-title":"Curr Opin Lipidol"},{"issue":"3","key":"5083_CR49","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","volume":"124","author":"S Wullschleger","year":"2006","unstructured":"Wullschleger S, Loewith R, Hall N. TOR signaling in growth andmetabolism. Cell. 2006;124(3):471\u201384.","journal-title":"Cell"},{"key":"5083_CR50","doi-asserted-by":"crossref","first-page":"435342","DOI":"10.1155\/2012\/435342","volume":"2012","author":"P Argyriou","year":"2012","unstructured":"Argyriou P, Economopoulou P, Papageorgiou S. The role of mTOR inhibitors for the treatment of B-cell lymphomas. Adv Hematol. 2012;2012:435342.","journal-title":"Adv Hematol"},{"issue":"19","key":"5083_CR51","doi-asserted-by":"crossref","first-page":"14071","DOI":"10.1074\/jbc.R109.094003","volume":"285","author":"K Foster","year":"2010","unstructured":"Foster K, Fingar D. Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J Biol Chem. 2010;285(19):14071\u201377.","journal-title":"J Biol Chem"},{"issue":"2","key":"5083_CR52","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274\u201393.","journal-title":"Cell"},{"issue":"2","key":"5083_CR53","doi-asserted-by":"crossref","first-page":"e88891","DOI":"10.1371\/journal.pone.0088891","volume":"9","author":"S Mori","year":"2014","unstructured":"Mori S, Nada S, Kimura H, Tajima S, Takahashi Y, Kitamura A, et al. The mTOR pathway controls cell proliferation by regulating the FoxO3 a transcription factor via SGK1 kinase. PLoS One. 2014;9(2):e88891.","journal-title":"PLoS One"},{"issue":"8","key":"5083_CR54","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1161\/CIRCRESAHA.111.246876","volume":"110","author":"BJ North","year":"2012","unstructured":"North BJ, Sinclair DA. The intersection between aging and cardiovascular disease. Circ Res. 2012;110(8):1097\u2013108.","journal-title":"Circ Res"},{"issue":"3","key":"5083_CR55","doi-asserted-by":"crossref","first-page":"R83","DOI":"10.1530\/ERC-12-0394","volume":"20","author":"RL Bitting","year":"2013","unstructured":"Bitting RL, Armstrong AJ. Targeting the PI3K\/Akt\/mTOR pathway in castration-resistant prostate cancer. Endocr Relat Cancer. 2013;20(3):R83\u201399.","journal-title":"Endocr Relat Cancer"},{"issue":"10","key":"5083_CR56","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/labinvest.2010.133","volume":"90","author":"CB Ching","year":"2010","unstructured":"Ching CB, Hansel DE. Expanding therapeutic targets in bladder cancer: the PI3K\/Akt\/mTOR pathway. Lab Invest. 2010;90(10):1406\u201314.","journal-title":"Lab Invest"},{"key":"5083_CR57","doi-asserted-by":"crossref","first-page":"709736","DOI":"10.1155\/2014\/709736","volume":"2014","author":"A Pavlidou","year":"2014","unstructured":"Pavlidou A, Vlahos NF. Molecular alterations of PI3K\/Akt\/mTOR pathway: a therapeutic target in endometrial cancer. Sci World J. 2014;2014:709736.","journal-title":"Sci World J"},{"key":"5083_CR58","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/1471-2407-13-250","volume":"13","author":"\u00c1 M\u00e1rk","year":"2013","unstructured":"M\u00e1rk \u00c1, Hajdu M, V\u00e1radi Z, Sticz TB, Nagy N, Csomor J, et al. Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease-a combined tissue microarray, in vitro and in vivo study. BMC Cancer. 2013;13:250.","journal-title":"BMC Cancer"},{"issue":"1","key":"5083_CR59","doi-asserted-by":"crossref","first-page":"49","DOI":"10.18632\/oncotarget.1548","volume":"5","author":"MG Francipane","year":"2014","unstructured":"Francipane MG, Lagasse E. mTOR pathway in colorectal cancer: an update. Oncotarget. 2014;5(1):49\u201366.","journal-title":"Oncotarget"},{"issue":"5","key":"5083_CR60","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374.","journal-title":"Cell"},{"issue":"2","key":"5083_CR61","doi-asserted-by":"crossref","first-page":"e55414","DOI":"10.1371\/journal.pone.0055414","volume":"8","author":"JA Ewald","year":"2013","unstructured":"Ewald JA, Downs TM, Cetnar JP, Ricke WA. Expression microarray meta-analysis identifies genes associated with Ras\/MAPK and related pathways in progression of muscle-invasive bladder transition cell carcinoma. PLoS One. 2013;8(2):e55414.","journal-title":"PLoS One"},{"issue":"2","key":"5083_CR62","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.3390\/ijms13021886","volume":"13","author":"H P\u00f3pulo","year":"2012","unstructured":"P\u00f3pulo H, Lopes JM, Soares P. The mTOR signalling pathway in human cancer. Int J Mol Sci. 2012;13(2):1886\u2013918.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"5083_CR63","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.3390\/cancers6031441","volume":"6","author":"T Matsuoka","year":"2014","unstructured":"Matsuoka T, Yashiro M. The role of PI3K\/Akt\/mTOR signaling in gastric carcinoma. Cancers (Basel). 2014;6(3):1441\u201363.","journal-title":"Cancers (Basel)"},{"issue":"21","key":"5083_CR64","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1007\/s00018-012-1129-8","volume":"69","author":"M Xu","year":"2012","unstructured":"Xu M, Mo YY. The Akt-associated microRNAs. Cell Mol Life Sci. 2012;69(21):3601\u201312.","journal-title":"Cell Mol Life Sci"},{"issue":"20","key":"5083_CR65","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1158\/1078-0432.CCR-14-1215","volume":"21","author":"J Kim","year":"2015","unstructured":"Kim J, Akbani R, Creighton CJ, Lerner SP, Weinstein JN, Getz G, et al. Invasive bladder cancer: genomic insights and therapeutic promise. Clin Cancer Res. 2015;21(20):4514\u201324.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"5083_CR66","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ctrv.2014.11.003","volume":"41","author":"BA Carneiro","year":"2015","unstructured":"Carneiro BA, Meeks JJ, Kuzel TM, Scaranti M, Abdulkadir SA, Giles FJ. Emerging therapeutic targets in bladder cancer. Cancer Treat Rev. 2015;41(2):170\u20138.","journal-title":"Cancer Treat Rev"},{"issue":"7492","key":"5083_CR67","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","volume":"507","author":"Cancer Genome Atlas Research Network Nature","year":"2014","unstructured":"Cancer Genome Atlas Research Network Nature. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315\u201322.","journal-title":"Nature"},{"key":"5083_CR68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2014.06.004","volume":"145","author":"N Hou\u00e9d\u00e9","year":"2015","unstructured":"Hou\u00e9d\u00e9 N, Pourquier P. Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: its potential use in the treatment of bladder cancers. Pharmacol Ther. 2015;145:1\u201318.","journal-title":"Pharmacol Ther"},{"issue":"6","key":"5083_CR69","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.2353\/ajpath.2010.090872","volume":"176","author":"DE Hansel","year":"2010","unstructured":"Hansel DE, Platt E, Orloff M, Harwalker J, Sethu S, Hicks JL, et al. Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma. Am J Pathol. 2010;176(6):3062\u201372.","journal-title":"Am J Pathol"},{"issue":"7","key":"5083_CR70","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/j.1365-2559.2011.03856.x","volume":"58","author":"CH Sun","year":"2011","unstructured":"Sun CH, Chang YH, Pan CC. Activation of the PI3K\/Akt\/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder. Histopathology. 2011;58(7):1054\u201363.","journal-title":"Histopathology"},{"key":"5083_CR71","doi-asserted-by":"crossref","first-page":"826","DOI":"10.2741\/2105","volume":"12","author":"R Abraham","year":"2007","unstructured":"Abraham R, Pagano F, Gomella LG, Baffa R. Chromosomal deletions in bladder cancer: shutting down pathways. Front Biosci. 2007;12:826\u201338.","journal-title":"Front Biosci"},{"key":"5083_CR72","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1101\/gad.1772909","volume":"23","author":"AM Puzio-Kuter","year":"2009","unstructured":"Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, Wang X, Shen TH, Matos T, et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev. 2009;23:675\u201380.","journal-title":"Genes Dev"},{"issue":"7","key":"5083_CR73","doi-asserted-by":"crossref","first-page":"466","DOI":"10.4111\/kju.2011.52.7.466","volume":"52","author":"SJ Park","year":"2011","unstructured":"Park SJ, Lee TJ, Chang IH. Role of the mTOR pathway in the progression and recurrence of bladder cancer: an immunohistochemical tissue microarray study. Korean J Urol. 2011;52(7):466\u201373.","journal-title":"Korean J Urol"},{"key":"5083_CR74","first-page":"885","volume":"53","author":"T Mukherjee","year":"2005","unstructured":"Mukherjee T, Shah BV. Sirolimus: a new immunosuppressant. J Assoc Physicians India. 2005;53:885\u201390.","journal-title":"J Assoc Physicians India"},{"issue":"5","key":"5083_CR75","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/j.transproceed.2008.03.150","volume":"40","author":"Y Shen","year":"2008","unstructured":"Shen Y, Wang X, Xia W, Wang C, Cai M, Xie H, et al. Antiproliferative and overadditive effects of rapamycin and FTY720 in pancreatic cancer cells in vitro. Transplant Proc. 2008;40(5):1727\u201333.","journal-title":"Transplant Proc"},{"key":"5083_CR76","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1756-9966-28-3","volume":"28","author":"R Pinto-Leite","year":"2009","unstructured":"Pinto-Leite R, Botelho P, Ribeiro E, Oliveira PA, Santos L. Effect of sirolimus on urinary bladder cancer T24 cell line. J Exp Clin Cancer Res. 2009;28:3.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"5083_CR77","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3390\/ijms14010273","volume":"14","author":"ZJ Dai","year":"2012","unstructured":"Dai ZJ, Gao J, Ma XB, Kang HF, Wang BF, Lu WF, et al. Antitumor effects of rapamycin in pancreatic cancer cells by inducing apoptosis and autophagy. Int J Mol Sci. 2012;14(1):273\u201385.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"5083_CR78","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1586\/era.12.151","volume":"13","author":"M Veroux","year":"2013","unstructured":"Veroux M, Tallarita T, Corona D, D\u2019Assoro A, Veroux P. Exploring new frontiers: sirolimus as a pharmacokinetic modulator in advanced cancer patients. Expert Rev Anticancer Ther. 2013;13(1):17\u201320.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"17","key":"5083_CR79","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-12-0110","volume":"18","author":"EE Cohen","year":"2012","unstructured":"Cohen EE, Wu K, Hartford C, Kocherginsky M, Eaton KN, Zha Y, et al. Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. Clin Cancer Res. 2012;18(17):4785\u201393.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"5083_CR80","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1517\/14740338.2012.713344","volume":"11","author":"RM Bukowski","year":"2012","unstructured":"Bukowski RM. Temsirolimus: a safety and efficacy review. Expert Opin Drug Saf. 2012;11(5):861\u201379.","journal-title":"Expert Opin Drug Saf"},{"issue":"11","key":"5083_CR81","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nrd3531","volume":"10","author":"D Benjamin","year":"2011","unstructured":"Benjamin D, Colombi M, Moroni C, Hall MN. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov. 2011;10(11):868\u201380.","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"5083_CR82","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2174\/187152010793498663","volume":"10","author":"H Zhou","year":"2010","unstructured":"Zhou H, Luo Y, Huang S. Updates of mTOR inhibitors. Anticancer Agents Med Chem. 2010;10(7):571\u201381.","journal-title":"Anticancer Agents Med Chem"},{"issue":"3","key":"5083_CR83","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/157488411797189433","volume":"6","author":"HD Husseinzadeh","year":"2011","unstructured":"Husseinzadeh HD, Garcia JA. Therapeutic rationale for mTOR inhibition in advanced renal cell carcinoma. Curr Clin Pharmacol. 2011;6(3):214\u201321.","journal-title":"Curr Clin Pharmacol"},{"issue":"1","key":"5083_CR84","first-page":"8","volume":"31","author":"HY Zhou","year":"2012","unstructured":"Zhou HY, Huang SL. Current development of the second generation of mTOR inhibitors as anticancer agents. Chin J Cancer. 2012;31(1):8\u201318.","journal-title":"Chin J Cancer"},{"issue":"7","key":"5083_CR85","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ctrv.2012.12.015","volume":"39","author":"SK Pal","year":"2013","unstructured":"Pal SK, Quinn DI. Differentiating mTOR inhibitors in renal cell carcinoma. Cancer Treat Rev. 2013;39(7):709\u201319.","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"5083_CR86","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520\u20139.","journal-title":"N Engl J Med"},{"issue":"6","key":"5083_CR87","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514\u201323.","journal-title":"N Engl J Med"},{"issue":"9","key":"5083_CR88","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1158\/1078-0432.CCR-09-3202","volume":"17","author":"E Chiong","year":"2011","unstructured":"Chiong E, Lee IL, Dadbin A, Sabichi AL, Harris L, Urbauer D, et al. Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells. Clin Cancer Res. 2011;17(9):2863\u201373.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"5083_CR89","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1158\/1535-7163.MCT-07-2408","volume":"7","author":"JA Garcia","year":"2008","unstructured":"Garcia JA, Danielpour D. Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther. 2008;7(6):1347\u201354.","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"5083_CR90","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1158\/0008-5472.CAN-07-6487","volume":"68","author":"B Shor","year":"2008","unstructured":"Shor B, Zhang WG, Toral-Barza L, Lucas J, Abraham RT, Gibbons JJ, et al. A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. Cancer Res. 2008;68(8):2934\u201343.","journal-title":"Cancer Res"},{"issue":"5","key":"5083_CR91","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3109\/0284186X.2013.776175","volume":"52","author":"KL Spindler","year":"2013","unstructured":"Spindler KL, Sorensen MM, Pallisgaard N, Andersen RF, Havelund BM, Ploen J, et al. Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma. Acta Oncol. 2013;52(5):963\u201370.","journal-title":"Acta Oncol"},{"issue":"10","key":"5083_CR92","doi-asserted-by":"crossref","first-page":"e26343","DOI":"10.1371\/journal.pone.0026343","volume":"6","author":"S Yang","year":"2011","unstructured":"Yang S, Xiao X, Meng X, Leslie KK. A mechanism for synergy with combined mTOR and PI3 kinase inhibitors. PLoS One. 2011;6(10):e26343.","journal-title":"PLoS One"},{"key":"5083_CR93","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.biomag.2014.03.003","volume":"4","author":"R Pinto-Leite","year":"2014","unstructured":"Pinto-Leite R, Arantes-Rodrigues R, Ferreira R, Palmeira C, Oliveira PA, Santos L. Treatment of muscle invasive urinary bladders tumors: a potential role of the mTOR inhibitors. Biomedicine & Aging Pathology. 2014;4:169\u201378.","journal-title":"Biomedicine & Aging Pathology"},{"issue":"8","key":"5083_CR94","first-page":"3221","volume":"29","author":"PA Oliveira","year":"2009","unstructured":"Oliveira PA, Arantes-Rodrigues R, Sousa-Diniz C, Cola\u00e7o A, Louren\u00e7o L, De La Cruz LF, et al. The effects of sirolimus on urothelial lesions chemically induced in ICR mice by BBN. Anticancer Res. 2009;29(8):3221\u20136.","journal-title":"Anticancer Res"},{"issue":"7","key":"5083_CR95","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.urolonc.2011.11.002","volume":"31","author":"C Vasconcelos-N\u00f3brega","year":"2013","unstructured":"Vasconcelos-N\u00f3brega C, Pinto-Leite R, Arantes-Rodrigues R, Ferreira R, Brochado P, Cardoso ML, et al. In vivo and in vitro effects of RAD001 on bladder cancer. Urol Oncol. 2013;31(7):1212\u201321.","journal-title":"Urol Oncol"},{"issue":"12","key":"5083_CR96","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1158\/1940-6207.CAPR-09-0169","volume":"2","author":"CM Seager","year":"2009","unstructured":"Seager CM, Puzio-Kuter AM, Patel T, Jain S, Cordon-Cardo C, Mc Kiernan J, et al. Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer. Cancer Prev Res (Phila). 2009;2(12):1008\u201314.","journal-title":"Cancer Prev Res (Phila)"},{"key":"5083_CR97","doi-asserted-by":"crossref","first-page":"146","DOI":"10.12659\/MSMBR.892514","volume":"20","author":"P Fong","year":"2014","unstructured":"Fong P, Meng LR. Effect of mTOR inhibitors in nude mice with endometrial carcinoma and variable PTEN expression status. Med Sci Monit Basic Res. 2014;20:146\u201352.","journal-title":"Med Sci Monit Basic Res"},{"issue":"7","key":"5083_CR98","first-page":"3329","volume":"34","author":"TH Chao","year":"2014","unstructured":"Chao TH, Chang GR, Chen WY, Chen PL, Mao FC. The synergistic effect of rapamycin combined with 5-fluorouracil in BALB\/cByJNarl mice bearing CT-26 tumor cells. Anticancer Res. 2014;34(7):3329\u201335.","journal-title":"Anticancer Res"},{"issue":"5","key":"5083_CR99","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s00280-013-2117-x","volume":"71","author":"DK Pawaskar","year":"2013","unstructured":"Pawaskar DK, Straubinger RM, Fetterly GJ, Hylander BH, Repasky EA, Ma WW, et al. Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice. Cancer Chemother Pharmacol. 2013;71(5):1231\u201340.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"5083_CR100","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1159\/000347063","volume":"97","author":"J Bollard","year":"2013","unstructured":"Bollard J, Couderc C, Blanc M, Poncet G, Lepinasse F, Hervieu V, et al. Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas. Neuroendocrinology. 2013;97(4):331\u201340.","journal-title":"Neuroendocrinology"},{"issue":"4","key":"5083_CR101","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1472-8206.2012.01035.x","volume":"27","author":"C Chu","year":"2013","unstructured":"Chu C, No\u00ebl-Hudson MS, Boige V, Go\u00e9r\u00e9 D, Marion S, Polrot M, et al. Therapeutic efficiency of everolimus and lapatinib in xenograft model of human colorectal carcinoma with KRAS mutation. Fundam Clin Pharmacol. 2013;27(4):434\u201342.","journal-title":"Fundam Clin Pharmacol"},{"issue":"5","key":"5083_CR102","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1158\/1078-0432.CCR-12-1904","volume":"19","author":"D Pachow","year":"2013","unstructured":"Pachow D, Andrae N, Kliese N, Angenstein F, Stork O, Wilisch-Neumann A, et al. mTORC1 inhibitors suppress meningioma growth in mouse models. Clin Cancer Res. 2013;19(5):1180\u20139.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"5083_CR103","doi-asserted-by":"crossref","first-page":"e55096","DOI":"10.1371\/journal.pone.0055096","volume":"8","author":"X Xie","year":"2013","unstructured":"Xie X, White EP, Mehnert JM. Coordinate autophagy and mTOR pathway inhibition enhances cell death in melanoma. PLoS One. 2013;8(1):e55096.","journal-title":"PLoS One"},{"issue":"7","key":"5083_CR104","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1111\/j.1349-7006.2011.01967.x","volume":"102","author":"T Ohara","year":"2011","unstructured":"Ohara T, Takaoka M, Toyooka S, Tomono Y, Nishikawa T, Shirakawa Y, et al. Inhibition of mTOR by temsirolimus contributes to prolonged survival of mice with pleural dissemination of non-small-cell lung cancer cells. Cancer Sci. 2011;102(7):1344\u20139.","journal-title":"Cancer Sci"},{"issue":"5","key":"5083_CR105","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1158\/0008-5472.CAN-12-3923","volume":"73","author":"JC Yao","year":"2013","unstructured":"Yao JC, Phan AT, Jehl V, Shah G, Meric-Bernstam F. Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience. Cancer Res. 2013;73(5):1449\u201353.","journal-title":"Cancer Res"},{"issue":"15","key":"5083_CR106","doi-asserted-by":"crossref","first-page":"e14542","DOI":"10.1200\/jco.2010.28.15_suppl.e14542","volume":"28","author":"LS Blaszkowsky","year":"2010","unstructured":"Blaszkowsky LS, Abrams TA, Miksad RA, Zheng H, Meyerhardt JA, Schrag D, et al. Phase I\/II study of everolimus in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2010;28(15):e14542.","journal-title":"J Clin Oncol"},{"issue":"1","key":"5083_CR107","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/jama.2014.7189","volume":"312","author":"A Zhu","year":"2014","unstructured":"Zhu A, Kudo M, Assenat E, Cattan S, Kang YK, Lim H, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib. The EVOLVE-1 randomized clinical trial. JAMA. 2014;312(1):57\u201367.","journal-title":"JAMA"},{"issue":"4","key":"5083_CR108","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1464-410X.2012.11720.x","volume":"112","author":"MI Milowsky","year":"2013","unstructured":"Milowsky MI, Iyer G, Regazzi AM, Al-Ahmadie H, Gerst SR, Ostrovnaya I, et al. Phase II study of everolimus in metastatic urothelial cancer. BJU Int. 2013;112(4):462\u201370.","journal-title":"BJU Int"},{"issue":"10","key":"5083_CR109","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1093\/annonc\/mds057","volume":"23","author":"E Seront","year":"2012","unstructured":"Seront E, Rottey S, Sautois B, Kerger J, D\u2019Hondt LA, Verschaeve V, et al. Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann Oncol. 2012;23(10):2663\u201370.","journal-title":"Ann Oncol"},{"key":"5083_CR110","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1371\/journal.pbio.1000038","volume":"7","author":"ME Feldman","year":"2009","unstructured":"Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1and mTORC2. PLoS Biol. 2009;7:e38.","journal-title":"PLoS Biol"},{"key":"5083_CR111","doi-asserted-by":"crossref","first-page":"8023","DOI":"10.1074\/jbc.M900301200","volume":"284","author":"CC Thoreen","year":"2009","unstructured":"Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem. 2009;284:8023\u201332.","journal-title":"J Biol Chem"},{"key":"5083_CR112","doi-asserted-by":"crossref","first-page":"567","DOI":"10.4161\/cc.8.4.7659","volume":"8","author":"AY Choo","year":"2009","unstructured":"Choo AY, Blenis J. Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. Cell Cycle. 2009;8:567\u201372.","journal-title":"Cell Cycle"},{"issue":"8","key":"5083_CR113","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1172\/JCI37539","volume":"120","author":"F Nicolantonio Di","year":"2010","unstructured":"Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest. 2010;120(8):2858\u201366.","journal-title":"J Clin Invest"},{"issue":"4","key":"5083_CR114","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.3892\/ol.2014.2392","volume":"8","author":"J Afonso","year":"2014","unstructured":"Afonso J, Longatto-Filho A, DA Silva M, Amaro T, Santos L. Phospho-mTOR in non-tumour and tumour bladder urothelium: pattern of expression and impact on urothelial bladder cancer patients. Oncol Lett. 2014;8(4):1447\u201354.","journal-title":"Oncol Lett"},{"issue":"1","key":"5083_CR115","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-014-0086-0","volume":"7","author":"WT Wang","year":"2014","unstructured":"Wang WT, Chen YQ. Circulating miRNAs in cancer: from detection to therapy. J Hematol Oncol. 2014;7(1):86.","journal-title":"J Hematol Oncol"},{"issue":"9","key":"5083_CR116","doi-asserted-by":"crossref","first-page":"6034","DOI":"10.1074\/jbc.M112.416446","volume":"288","author":"H Totary-Jain","year":"2013","unstructured":"Totary-Jain H, Sanoudou D, Ben-Dov IZ, Dautriche CN, Guarnieri P, Marx SO, et al. Reprogramming of the microRNA transcriptome mediates resistance to rapamycin. J Biol Chem. 2013;288(9):6034\u201344.","journal-title":"J Biol Chem"},{"issue":"2","key":"5083_CR117","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.3390\/ijms14023874","volume":"14","author":"N Alqurashi","year":"2013","unstructured":"Alqurashi N, Hashimi SM, Wei MQ. Chemical inhibitors and microRNAs (miRNA) targeting the mammalian target of rapamycin (mTOR) pathway: potential for novel anticancer therapeutics. Int J Mol Sci. 2013;14(2):3874\u2013900.","journal-title":"Int J Mol Sci"},{"issue":"13","key":"5083_CR118","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1200\/JCO.2008.20.0766","volume":"27","author":"F Meric-Bernstam","year":"2009","unstructured":"Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol. 2009;27(13):2278\u201387.","journal-title":"J Clin Oncol"},{"key":"5083_CR119","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.critrevonc.2013.08.008","volume":"89","author":"L Cheng","year":"2014","unstructured":"Cheng L, Davison D, Adams J, Lopez-Beltran A, Wang L, Montironi R, et al. Biomarkers in bladder cancer: translational and clinical implications. Crit Rev Oncol Hematol. 2014;89:73\u2013111.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"5083_CR120","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1007\/s13277-013-1604-3","volume":"35","author":"R Pinto-Leite","year":"2014","unstructured":"Pinto-Leite R, Carreira I, Melo J, Ferreira SI, Ribeiro I, Ferreira J, et al. Genomic characterization of three urinary bladder cancer cell lines: understanding genomic types of urinary bladder cancer. Tumour Biol. 2014;35(5):4599\u2013617.","journal-title":"Tumour Biol"},{"key":"5083_CR121","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1186\/1471-2407-14-966","volume":"14","author":"V Vashistha","year":"2014","unstructured":"Vashistha V, Quinn DI, Dorff TB, Daneshmand S. Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review. BMC Cancer. 2014;14:966.","journal-title":"BMC Cancer"},{"issue":"2","key":"5083_CR122","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1586\/era.11.201","volume":"12","author":"RM Drayton","year":"2012","unstructured":"Drayton RM, Catto W. Molecular mechanisms of cisplatin resistance in bladder cancer. Expert Rev Anticancer Ther. 2012;12(2):271\u201381.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"5083_CR123","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.urolonc.2013.04.012","volume":"32","author":"R Pinto-Leite","year":"2014","unstructured":"Pinto-Leite R, Arantes-Rodrigues R, Ferreira R, Palmeira C, Cola\u00e7o A, da Silva MV, et al. Temsirolimus improves cytotoxic efficacy of cisplatin and gemcitabine against urinary bladder cancer cell lines. Urol Oncol. 2014;32(1):41. e11\u201322.","journal-title":"Urol Oncol"},{"issue":"4","key":"5083_CR124","doi-asserted-by":"crossref","first-page":"904","DOI":"10.3892\/ijmm.2013.1282","volume":"31","author":"Y Cai","year":"2013","unstructured":"Cai Y, Xia Q, Su Q, Luo R, Sun Y, Shi Y, et al. mTOR inhibitor RAD001 (everolimus) induces apoptotic, not autophagic cell death, in human nasopharyngeal carcinoma cells. Int J Mol Med. 2013;31(4):904\u201312.","journal-title":"Int J Mol Med"},{"issue":"4","key":"5083_CR125","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s10637-009-9269-x","volume":"28","author":"BB Ma","year":"2010","unstructured":"Ma BB, Lui VW, Hui EP, Lau CP, Ho K, Ng MH, et al. The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines. Invest New Drugs. 2010;28(4):413\u201320.","journal-title":"Invest New Drugs"},{"issue":"8","key":"5083_CR126","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1158\/1078-0432.CCR-12-2293","volume":"19","author":"Y Pignochino","year":"2013","unstructured":"Pignochino Y, Dell\u2019Aglio C, Basirico M, Capozzi F, Soster M, Marchio S, et al. The combination of sorafenib and everolimus abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models. Clin Cancer Res. 2013;19(8):2117\u201331.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"5083_CR127","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.18632\/oncotarget.762","volume":"3","author":"F Chiarini","year":"2012","unstructured":"Chiarini F, Lonetti A, Teti G, Orsini E, Bressanin D, Cappellini A, et al. A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. Oncotarget. 2012;3(12):1615\u201328.","journal-title":"Oncotarget"},{"issue":"3","key":"5083_CR128","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.urolonc.2013.06.002","volume":"32","author":"M Becker","year":"2014","unstructured":"Becker M, Wu K, Marlowc A, Kreinestc P, von Roemelingc C, Copland J, et al. The combination of an mTORc1\/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro. Urol Oncol. 2014;32(3):317\u201326.","journal-title":"Urol Oncol"},{"issue":"5","key":"5083_CR129","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1165\/rcmb.2015-0022OC","volume":"53","author":"A Alayev","year":"2015","unstructured":"Alayev A, Salamon RS, Sun Y, Schwartz NS, Li C, Yu JJ, et al. Effects of combining rapamycin and resveratrol on apoptosis and growth of TSC2-deficient xenograft tumors. Am J Respir Cell Mol Biol. 2015;53(5):637\u201346.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"6","key":"5083_CR130","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1158\/1535-7163.MCT-10-0666","volume":"10","author":"AC Piguet","year":"2011","unstructured":"Piguet AC, Saar B, Hlushchuk R, St-Pierre MV, McSheehy PM, Radojevic V, et al. Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma. Mol Cancer Ther. 2011;10(6):1007\u201317.","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"5083_CR131","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.bcp.2012.01.013","volume":"83","author":"Q Zhou","year":"2012","unstructured":"Zhou Q, Lui VW, Lau CP, Cheng SH, Ng MH, Cai Y, et al. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus\/vinblastine combination in hepatocellular carcinoma. Biochem Pharmacol. 2012;83(9):1146\u201358.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"5083_CR132","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11523-013-0267-8","volume":"9","author":"S Sikaria","year":"2013","unstructured":"Sikaria S, Heim-Hall J, Diaz EH, Williams R, Sankhala K, Laabs B, et al. Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717\u2013454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor. Target Oncol. 2013;9(1):73\u20139.","journal-title":"Target Oncol"},{"issue":"3","key":"5083_CR133","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00280-014-2376-1","volume":"73","author":"P Cirone","year":"2014","unstructured":"Cirone P, Andresen J, Eswaraka R, Lappin B, Bagi CM. Patient-derived xenografts reveal limits to PI3K\/mTOR- and MEK-mediated inhibition of bladder cancer. Cancer Chemother Pharmacol. 2014;73(3):525\u201338.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"5083_CR134","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s12032-009-9220-1","volume":"27","author":"H Gerullis","year":"2010","unstructured":"Gerullis H, Bergmann L, Maute L, Ecke TH, Eimer C, Bagner JW, et al. Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma. Med Oncol. 2010;27(2):373\u20138.","journal-title":"Med Oncol"},{"issue":"1","key":"5083_CR135","first-page":"21","volume":"33","author":"P Malaguti","year":"2013","unstructured":"Malaguti P, Vari S, Cognetti F, Fabi A. The Mammalian target of rapamycin inhibitors in breast cancer: current evidence and future directions. Anticancer Res. 2013;33(1):21\u20138.","journal-title":"Anticancer Res"},{"issue":"9","key":"5083_CR136","doi-asserted-by":"crossref","first-page":"6511","DOI":"10.1074\/jbc.M112.399485","volume":"288","author":"AK Murugan","year":"2013","unstructured":"Murugan AK, Alzahrani A, Xing M. Mutations in critical domains confer the human mTOR gene strong tumorigenicity. J Biol Chem. 2013;288(9):6511\u201321.","journal-title":"J Biol Chem"}],"container-title":["Tumor Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-016-5083-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13277-016-5083-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-016-5083-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-016-5083-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,8]],"date-time":"2019-09-08T23:31:46Z","timestamp":1567985506000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13277-016-5083-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,27]]},"references-count":136,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["5083"],"URL":"https:\/\/doi.org\/10.1007\/s13277-016-5083-1","relation":{},"ISSN":["1010-4283","1423-0380"],"issn-type":[{"value":"1010-4283","type":"print"},{"value":"1423-0380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,27]]}}}